Close Menu
World Economist – Global Markets, Finance & Economic Insights
  • Home
  • Economist Impact
    • Economist Intelligence
    • Finance & Economics
  • Business
  • Asia
  • China
  • Europe
  • Economy
  • USA
    • Middle East & Africa
    • Highlights
  • This week
  • World Economy
    • World News
What's Hot

China’s lead in global shipbuilding may already be fading, new data suggests

July 9, 2025

Why EU capitals are irate at German car swap scheme to swerve US tariffs

July 9, 2025

Indonesia to press on with US trade talks despite 32% tariff: ‘very optimistic’

July 9, 2025
Facebook X (Twitter) Instagram
Wednesday, July 9
Facebook X (Twitter) Instagram
World Economist – Global Markets, Finance & Economic Insights
  • Home
  • Economist Impact
    • Economist Intelligence
    • Finance & Economics
  • Business
  • Asia
  • China
  • Europe
  • Economy
  • USA
    • Middle East & Africa
    • Highlights
  • This week
  • World Economy
    • World News
World Economist – Global Markets, Finance & Economic Insights
Home » Price deregulation improves access to medicines, helps stabilise industry – Business & Finance
Economist Intelligence

Price deregulation improves access to medicines, helps stabilise industry – Business & Finance

adminBy adminMay 12, 2025No Comments4 Mins Read
Share Facebook Twitter Pinterest Copy Link LinkedIn Tumblr Email VKontakte Telegram
Share
Facebook Twitter Pinterest Email Copy Link
Post Views: 73


KARACHI: The price deregulation of non-essential medicines in early 2024 has improved access to medicines and brought much-needed stability to the pharmaceutical sector, creating space for sustainable and long-term industry growth.

The policy shift, aimed to create a market-driven approach while addressing longstanding challenges in the sector, provided flexibility to pharmaceutical firms, allowing them to adjust prices in line with market conditions.

By aligning prices with inflation and currency fluctuations, companies have managed to stabilise production of medicines that were previously at risk of becoming unavailable due to pricing constraints, according to experts.

Pharma sector: SIFC backs deregulation as exports surge

Contrary to the skepticism surrounding price deregulation, the past year has proven it to be a correction rather than a market free-for-all.

Essential medicines—listed under the National Essential Medicines List (NEML)—remain under strict government’s price controls, ensuring continued affordability for vulnerable populations. However, by removing artificial price ceilings on non-essential medicines, the government restored confidence among manufacturers and revived production lines.

“This (deregulation) was not about letting prices run wild, but it was about saving healthcare industry on the verge of collapse and increasing access of patients to genuine medicines at market price,” said a former Pakistan Pharmaceutical Manufacturers’ Association (PPMA) chairman. “Deregulation has balanced sustainability with patient access.”

With production becoming financially viable, many life-saving but previously discontinued drugs are now back on shelves. The volume of medicines sold rose by 3.79% year-over-year, according to IQVIA data dated February 2025, countering claims that higher prices have reduced access.

Stable supply chains have also curtailed the rise of unregulated and counterfeit substitutes that had filled the void during previous shortages.

Deregulation brings innovation, investment

The economic impact of deregulation has been supportive. In the first quarter of FY25, the sector recorded a 5.6-fold increase in profitability, jumping to Rs5.6 billion from Rs1 billion in the same quarter of FY24, according to Topline Research.

The growth was driven by improved margins, reduced financing costs, and greater production efficiency.

The profitability has translated into increased investment. PPMA member companies are rapidly upgrading their manufacturing facilities to meet WHO PQ and PIC/S standards. The improvements can position Pakistan to significantly expand exports to regulated markets across Asia, the Middle East, and Africa.

PPMA officials estimate that Pakistan’s pharmaceutical exports significantly surged to $500 million in the first half of FY25, suggesting having potential to reach $1 billion in full-year FY25 and $5 billion in the next five years, provided deregulation and policy stability remain in place.

“Global buyers are now viewing Pakistan as a reliable, high-quality supplier,” a PPMA spokesperson said. “This is a major shift from just two years ago.”

According to industry sources, Pakistan and Afghanistan are to reach an understanding in the healthcare sector, enabling Islamabad tap around $500 million export potential in the neighbouring country.

Stock performance soars

Market sentiment has surged in response to these developments. The pharmaceutical sector’s value climbed 194% year-to-date, far outpacing the KSE-100 Index (which rose 84%), it was learnt. For the first time in years, pharma stocks are among the top-performing equities at the Pakistan Stock Exchange (PSX).

Haleon posted a staggering 436% gain year to date, Glaxo rose by 362%, Macter gained 315%, while AGP is expected to continued performing well this year; 2025.

PPMA continues to advocate for a rule-based, transparent pricing mechanism for the sector, while ensuring that essential drugs remain affordable and accessible. The association is also calling for strengthened collaboration with the Drug Regulatory Authority of Pakistan (DRAP) and the Ministry of Health to prevent market abuse, reinforce public trust, and build a more innovation-driven ecosystem.

“This is not just a recovery story—it’s a growth story,” said the former PPMA chairman. “The reforms have given Pakistan’s pharmaceutical industry a new identity: competitive, credible, and caring.”

Copyright Business Recorder, 2025



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email Telegram Copy Link
admin
  • Website

Related Posts

Economist Intelligence

Auto disconnection of POS system: FTO directs FBR to develop forewarning system – Business & Finance

July 9, 2025
Economist Intelligence

SECP records 35,000 company incorporations in FY2024-25 – Business & Finance

July 9, 2025
Economist Intelligence

NSPC merges with and into PSPC – Business & Finance

July 9, 2025
Economist Intelligence

Trump announces 50pc tariff on copper imports – World

July 9, 2025
Economist Intelligence

Pakistan’s Rs7.2trn annual debt burden should finance growth-generating activities, says think tank – Pakistan

July 8, 2025
Economist Intelligence

Pakistan approves four potential bidders for struggling national airline PIA – Pakistan

July 8, 2025
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

Auto disconnection of POS system: FTO directs FBR to develop forewarning system – Business & Finance

July 9, 2025

SECP records 35,000 company incorporations in FY2024-25 – Business & Finance

July 9, 2025

NSPC merges with and into PSPC – Business & Finance

July 9, 2025

Trump announces 50pc tariff on copper imports – World

July 9, 2025
Latest Posts

PSX hits all-time high as proposed ‘neutral-to-positive’ budget well-received by investors – Business

June 11, 2025

Sindh govt to allocate funds for EV taxis, scooters in provincial budget: minister – Pakistan

June 11, 2025

US, China reach deal to ease export curbs, keep tariff truce alive – World

June 11, 2025

Subscribe to News

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Recent Posts

  • China’s lead in global shipbuilding may already be fading, new data suggests
  • Why EU capitals are irate at German car swap scheme to swerve US tariffs
  • Indonesia to press on with US trade talks despite 32% tariff: ‘very optimistic’
  • Malaysia police hunt priest accused of molesting beauty queen at Hindu temple ‘blessing’
  • Auto disconnection of POS system: FTO directs FBR to develop forewarning system – Business & Finance

Recent Comments

No comments to show.

Welcome to World-Economist.com, your trusted source for in-depth analysis, expert insights, and the latest news on global finance and economics. Our mission is to provide readers with accurate, data-driven reports that shape the understanding of economic trends worldwide.

Latest Posts

China’s lead in global shipbuilding may already be fading, new data suggests

July 9, 2025

Why EU capitals are irate at German car swap scheme to swerve US tariffs

July 9, 2025

Indonesia to press on with US trade talks despite 32% tariff: ‘very optimistic’

July 9, 2025

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

Archives

  • July 2025
  • June 2025
  • May 2025
  • April 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • June 2024
  • October 2022
  • March 2022
  • July 2021
  • February 2021
  • January 2021
  • November 2019
  • April 2011
  • January 2011
  • December 2007
  • July 2007

Categories

  • AI & Tech
  • Asia
  • Banking
  • Business
  • Business
  • China
  • Climate
  • Computing
  • Economist Impact
  • Economist Intelligence
  • Economy
  • Editor's Choice
  • Europe
  • Europe
  • Featured
  • Featured Business
  • Featured Climate
  • Featured Health
  • Featured Science & Tech
  • Featured Travel
  • Finance & Economics
  • Health
  • Highlights
  • Markets
  • Middle East
  • Middle East & Africa
  • Middle East News
  • Most Viewed News
  • News Highlights
  • Other News
  • Politics
  • Russia
  • Science
  • Science & Tech
  • Social
  • Space Science
  • Sports
  • Sports Roundup
  • Tech
  • This week
  • Top Featured
  • Travel
  • Trending Posts
  • Ukraine Conflict
  • Uncategorized
  • US Politics
  • USA
  • World
  • World & Politics
  • World Economy
  • World News
© 2025 world-economist. Designed by world-economist.
  • Home
  • About Us
  • Advertise With Us
  • Contact Us
  • DMCA
  • Privacy Policy
  • Terms & Conditions

Type above and press Enter to search. Press Esc to cancel.